Logo

Formycon and Klinge Biopharma Reports the US FDA’s Approval of Ahzantive (Biosimilar, Eylea)

Share this
Formycon

Formycon and Klinge Biopharma Reports the US FDA’s Approval of Ahzantive (Biosimilar, Eylea)

Shots:

  • The US FDA has approved Formycon and Klinge Biopharma’s Ahzantive (aflibercept-mrbb), biosimilar of Eylea, for treating Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases incl. Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Macular Edema following Retinal Vein Occlusion (RVO) 
  • The approval was based on analytical, pre-clinical, clinical and manufacturing data shown similar efficacy, safety, PK & immunogenicity in Age-Related Neovascular (wet) Macular Degeneration (nAMD) patients 
  • MAA was also submitted to the EMA in 2023, the decision of which is anticipated in early 2025 

Ref: FORMYCON | Image: FORMYCON

Related News:- Formycon and its License Partner Klinge Biopharma Reports the BLA Submission of FYB203 (Biosimilar, Eylea) to the EMA

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Dipanshu Dixit

A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions